---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-116847"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:22:45.601569+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint doses first patient in Phase 3 LUGANO trial of DURAVYU for wet AMD; LUCIA trial by end 2024, topline 2026

## Summary
- First patient dosed in global Phase 3 LUGANO trial of DURAVYU (vorolanib) for wet AMD; non-inferiority design vs aflibercept.
- Second Phase 3 LUCIA trial first dosing expected by end of 2024; topline data anticipated in 2026.
- Trials enroll ~400 patients each; DURAVYU dosed every 6 months vs on-label aflibercept every 2 months, after 3 loading doses.
- Over 190 patients previously treated in DAVIO/DAVIO 2; favorable safety; treatment-naïve and treatment-experienced included.
- Re-dosing evaluated in both trials; primary endpoint: average change in BCVA at weeks 52 and 56 vs baseline.

## SEC filing metadata
- accession: 0000950170-24-116847
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/0000950170-24-116847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/eypt-20241022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-116847
- JSON: https://secwatch.observer/filing/0000950170-24-116847.json
- Plain text: https://secwatch.observer/filing/0000950170-24-116847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.